Source comparison
Thymosin Alpha-1 vs TA-1: Clinical Applications Comparison
Research-grade in vitro studies Standard nomenclature in methods sections Abbreviated form in figures and legends Not applicable. Clinical formulation only Both names refer to the same peptide. Verify sequence and purity via COA Preclinical animal models Used
This comparison does not assign a generated winner or score.
- Research-grade in vitro studies
- Standard nomenclature in methods sections
- Abbreviated form in figures and legends
- Not applicable. Clinical formulation only
- Both names refer to the same peptide. Verify sequence and purity via COA
- Preclinical animal models
- Used in dosing protocols and pharmacokinetic analysis
- Common in immunology journals
- Not applicable
- Nomenclature choice reflects publication style, not compound identity
- Clinical trial documentation
- Formal INN name in regulatory filings
- Rare in clinical literature
- WHO-designated name for pharmaceutical product
- Thymalfasin = thymosin alpha-1 = TA-1 at the molecular level
- Commercial drug product (international markets)
- Generic descriptor
- Not used in branding
- Branded formulation (1.6 mg subcutaneous)
- Zadaxin contains TA-1. Same sequence, GMP manufacturing
- Supplier catalogs
- Full chemical name
- Abbreviated catalog listing
- Not sold as research-grade reagent
- Both listings describe identical 28-amino-acid peptide
- Regulatory filings (FDA, EMA)
- Required formal name
- Acceptable parenthetical abbreviation
- Designated INN for drug approval
- All three terms may appear in the same regulatory document